dynaMX Compression Staple

K143622 · Mx Orthopedics, Corp. · JDR · Jun 17, 2015 · Orthopedic

Device Facts

• Record ID: K143622
• Device Name: dynaMX Compression Staple
• Applicant: Mx Orthopedics, Corp.
• Product Code: JDR · Orthopedic
• Decision Date: Jun 17, 2015
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3030
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The dynaMX Compression Staple is indicated for: Fracture and osteotomy fixation and joint arthrodesis of the hand and foot and, Fixation of proximal tibial metaphysis osteotomy

Device Story

dynaMX Compression Staple is a metallic bone fixation device; fabricated from biocompatible Nitinol; utilizes superelastic properties of Nitinol legs to provide continuous compression across bone segments. Used by orthopedic surgeons in clinical settings for fracture management, reconstructive surgery, and joint arthrodesis. Staples with bridge lengths ≥11mm are bendable to contour to bone surfaces. Device provides mechanical stability to bone fragments during healing; benefits patient by maintaining compression across osteotomy or fracture sites to promote fusion/union.

Clinical Evidence

Bench testing only. Studies included elastic static bending testing, bending fatigue testing, staple pull-out force testing, and corrosion testing. Biocompatibility of Nitinol is established via reference literature. No clinical data provided.

Technological Characteristics

Material: Nitinol (biocompatible). Principle: Superelastic compression via staple legs. Form factor: Staple with bendable bridge (for lengths ≥11mm). Energy source: None (passive mechanical). Sterilization: Not specified.

Indications for Use

Indicated for fracture/osteotomy fixation and joint arthrodesis of the hand and foot, and fixation of proximal tibial metaphysis osteotomy in patients requiring bone fixation.

Regulatory Classification

Identification

Single/multiple component metallic bone fixation appliances and accessories are devices intended to be implanted consisting of one or more metallic components and their metallic fasteners. The devices contain a plate, a nail/plate combination, or a blade/plate combination that are made of alloys, such as cobalt-chromium-molybdenum, stainless steel, and titanium, that are intended to be held in position with fasteners, such as screws and nails, or bolts, nuts, and washers. These devices are used for fixation of fractures of the proximal or distal end of long bones, such as intracapsular, intertrochanteric, intercervical, supracondylar, or condylar fractures of the femur; for fusion of a joint; or for surgical procedures that involve cutting a bone. The devices may be implanted or attached through the skin so that a pulling force (traction) may be applied to the skeletal system.

Predicate Devices

• Speed™ Staple (K102107)
• OSStaple™ Staple (K993714)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and features the department's name around the perimeter. In the center of the logo is an abstract symbol of a human figure, represented by three overlapping profiles.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

June 17, 2015

MX Orthopedics, Corporation Mr. Howard L. Schrayer Regulatory Affairs Consultant 12 Suburban Park Drive Billerica, Massachusetts 01821

Re: K143622

Trade/Device Name: dynaMX™ Compression Staple Regulation Number: 21 CFR 888.3030 Regulation Name: Single/multiple component metallic bone fixation appliances and accessories Regulatory Class: Class II Product Code: JDR Dated: May 8, 2015 Received: May 11, 2015

Dear Mr. Schrayer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing

{1}------------------------------------------------

(21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Lori A. Wiggins -S

for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Form Approved: OMB No. 0910-0120

Expiration Date: January 31, 2017

See PRA Statement below.

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# Indications for Use

510(k) Number (if known) K143622

Device Name dynaMX Compression Staple

Indications for Use (Describe)

The dynaMX Compression Staple is indicated for:

Fracture and osteotomy fixation and joint arthrodesis of the hand and foot and, Fixation of proximal tibial metaphysis osteotomy

| Type of Use (Select one or both, as applicable) | | | | | |
|-------------------------------------------------|--|--|--|--|--|
|-------------------------------------------------|--|--|--|--|--|

> Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

### 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS (Per 21 CFR 807.92)

### General Company Information

| Name:<br>Contact: | MX Orthopedics, Corp.<br>Howard Schrayer<br>Regulatory Affairs Consultant |
|--------------------|---------------------------------------------------------------------------|
| Address: | 12 Suburban Park Drive<br>Billerica, MA 01821 |
| Telephone:<br>Fax: | (978) 294 - 8114<br>(978) 232 - 9998 |
| Date Prepared | June 12, 2015 |

### General Device Information

| Product Name: | dynaMX TM Compression Staple |
|-----------------|---------------------------------------------------------------------------|
| Classification: | "Bone Fixation Staple"<br>Product code: JDR - Class II<br>21 CFR 888.3030 |

#### Predicate Device

| BioMedical Enterprises | Speed™ Staple<br>(Originally cleared as Osstaple™ Chill)<br>[510(k) Number K102107] |
|------------------------|-------------------------------------------------------------------------------------|
| BioMedical Enterprises | OSStaple™ Staple<br>(Originally cleared as Memograph™)<br>[510(k) K993714] |

{4}------------------------------------------------

# Description

The dynaMX Compression Staple provides a means of bone fixation in the management of fractures and reconstructive surgery.

- . The dynaMX Compression Staples are made of biocompatible Nitinol. The legs of the staple are designed to exhibit superelastic properties at room temperature.
- Staples with a bridge length of 11mm and longer are designed with a bridge that can . be bent to contour to the bone surface.

# Indications for Use

The dynaMX™ Compression Staple is indicated for:

- 0 Fracture and osteotomy fixation and joint arthrodesis of the hand and foot and,
- Fixation of proximal tibial metaphysis osteotomy 0

# Substantial Equivalence

A series of laboratory studies (bench tests) have been conducted to verify the suitability of the dynaMX™ Compression Staple for its intended use, establish Substantial Equivalence with the predicate devices and confirm reproducibility of the packaging.

These tests include:

Elastic Static Bending Testing Bending Fatigue Testing Staple Pull-Out Force Corrosion Testing Package Seal Strength Verification

The biocompatibility of Nitinol has been well-established. A reference publication that describes the biocompatibility is also appended, together with a copy of the shelf-life / stability protocol.

This submission supports the position that the MX Orthopedics dvnaMX™ Compression Staple is substantially equivalent to previously cleared devices, including those listed above. A number of predicate devices list the same range of clinical uses.

# Conclusions

MX Orthopedics, Corp. believes that the information provided establishes that similar legally marketed devices have been used for the same clinical applications as the MX Orthopedics dynaMX™ Compression Staple. The materials from which the MX Orthopedics device is fabricated have an established history of use, and the devices have been tested in accordance with applicable FDA guidelines.